Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.39 |
| ▸ | ACACA | Q13085 | 6/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215991 | 0.94 | ACACB (0.39) | ACACBACACAGPR119RAB9AHRH3 | |
| SCHEMBL2215997 | 0.94 | ACACB (0.39) | ACACBACACAGPR119RAB9AHRH3 | |
| SCHEMBL13536455 | 0.90 | ACACB (0.40) | ACACBACACAGPR119RAB9ANPC1 | |
| SCHEMBL2218938 | 0.89 | ACACB (0.40) | ACACBACACAGPR119RAB9AHRH3 | |
| SCHEMBL2217772 | 0.89 | ACACB (0.40) | ACACBACACAGPR119HRH3 | |
| SCHEMBL2215398 | 0.89 | ACACB (0.40) | ACACBACACAGPR119HRH3 | |
| SCHEMBL2216319 | 0.88 | HRH3 (0.41) | ACACBACACAGPR119HRH3 | |
| SCHEMBL2217126 | 0.88 | ACACB (0.38) | ACACBACACAGPR119RAB9AHRH3 | |
| SCHEMBL2217846 | 0.88 | ACACB (0.38) | ACACBACACAGPR119S1PR1S1PR3 | |
| SCHEMBL2217852 | 0.88 | ACACB (0.38) | ACACBACACAGPR119S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | ACACB 2654/4885ACACA 2114/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.